Joint Filing AgreementJoint Filing Agreement • April 4th, 2022 • Biotechnology Value Fund L P • Investment advice
The undersigned hereby agree that the Statement on Schedule 13G dated April 4, 2022 with respect to the Common Stock, $0.00001 par value per share of AN2 Therapeutics, Inc., a Delaware corporation, and any further amendments thereto executed by each and any of the undersigned shall be filed on behalf of each of the undersigned pursuant to and in accordance with the provisions of Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended.
